Efficacy and tolerability of brodimoprim in otitis.
Eighty adult patients affected by acute bacterial otitis media were selected and randomized into two balanced groups of treatment: 1) brodimoprim 200 mg tablets at the dosage of 2 tablets in single dose on the first day and one tablet on the following days; 2) josamycin 500 mg tablets at the dosage of 3 tablets/day. The average duration of treatment was 8 days: all patients completed the trial. The symptoms were evaluated by score method (on the 3rd, 7th and on the last day of therapy) and a thermometric curve was made daily. Microbiological examination of the exudate was performed in the patients with auricular discharge (28), at the beginning of the treatment and 7 days after the end of therapy. The tolerability was assessed through registration of side effects. Brodimoprim resulted more effective in the reduction of hypoacusis and tinnitus; other symptoms demonstrated higher percentage reductions in the group under brodimoprim therapy. Bacteriological exams were negative at the second checkup, except in 6 patients (3 per group). Side effects were reported in 5 patients (12.5%) treated with brodimoprim and in 9 (22.5%) treated with josamycin. Abnormal values in laboratory tests were not observed.
De Campora
E
E
ENT Dpt. General Hospital S. Giovanni Calibita, Roma, Italy.
Radici
M
M
Camaioni
A
A
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections; D004361:Drug Tolerance; D005122:Exudates and Transudates / Q000382:microbiology; D005260:Female; D006801:Humans; D015570:Josamycin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010033:Otitis Media / Q000188:drug therapy* / Q000382:microbiology; D014295:Trimethoprim / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D014295:Trimethoprim; D015570:Josamycin; C037079:brodimoprim